Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02996812 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia
A Phase 1 study of Hyperinsulinemia Hypoglycemia, sponsored by Tracey McLaughlin.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT02996812 is a Phase 1 study of Hyperinsulinemia Hypoglycemia that has completed, run by Tracey McLaughlin. The registered enrollment target is 9 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02996812, a Phase 1 study of Hyperinsulinemia Hypoglycemia, has completed, sponsored by Tracey McLaughlin.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to evaluate the safety, efficacy, and pharmacokinetic profile of single ascending doses of exendin 9-39 administered by subcutaneous route in subjects with post-bariatric hypoglycemia.
Conditions Studied
Interventions
- DRUG Exendin (9-39)
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02996812
The ClinicalTrials.gov registry entry for NCT02996812 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tracey McLaughlin, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hyperinsulinemia Hypoglycemia appearing as the primary indexed condition, and to 1 intervention - of which Exendin (9-39) is the first listed.
NCT02996812 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02996812 about?
NCT02996812 is a clinical study titled "Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia". This study is designed to evaluate the safety, efficacy, and pharmacokinetic profile of single ascending doses of exendin 9-39 administered by subcutaneous route in subjects with post-bariatric hypoglycemia.
What is the current status of trial NCT02996812?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2015-04. Estimated completion is 2016-08.
What conditions does trial NCT02996812 study?
This clinical trial studies the following conditions: Hyperinsulinemia Hypoglycemia.
What interventions are being tested in trial NCT02996812?
The interventions under investigation include: Exendin (9-39) (DRUG).
Who is sponsoring clinical trial NCT02996812?
This trial is sponsored by Tracey McLaughlin, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02996812 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.